Fibrocell Science‘s gene therapy candidate FCX-013 received fast track designation by the U.S. Food and Drug Administration as…
Articles by Alice Melão, MSc
High-frequency ultrasound (HFU) of the skin can help evaluate the progression and define disease activity in patients with systemic sclerosis…
Emerald Health Pharmaceuticals’ lead cannabinoid-derived treatment candidate, EHP-101, has shown potential to prevent skin and lung tissue scaring in…
Treatment with Corbus Pharmaceuticals’ investigative therapy lenabasum (formerly known as anabasum) significantly improves the symptoms of diffuse cutaneous…
Approximately 85 percent of Canadians with pulmonary arterial hypertension (PAH) and systemic sclerosis (SSc) now have access to…
Lenabasum, an investigational treatment of diffuse cutaneous systemic sclerosis by Corbus Pharmaceuticals, was shown to be safe, well-tolerated and of…
Early diagnosis and prompt treatment was found to be critical in achieving better long-term outcomes for children with juvenile…
Increased levels of two proteins produced during acute inflammation can help predict pulmonary involvement in patients with diffuse systemic sclerosis,…
iBio has selected a lead scleroderma treatment candidate — a molecule it calls the E4-Fc fusion protein. The company…
Boehringer Ingelheim and the Scleroderma Foundation have started a global initiative to raise awareness of scleroderma and support those…